HIM
AEON.WS

HGC Investment Management’s AEON Biopharma Inc AEON.WS Stock Holding History

HGC Investment Management’s Portfolio AEON.WS Stock Details AEON.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-83,333
Closed -$4K – 271
2022
Q4 		$4K Buy
+83,333
New +$3.37K ﹤0.01% 287

Other funds holding AEON.WS

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

HGC Investment Management's AEON.WS Position: Q1 2023 in Review

HGC Investment Management sold out of AEON Biopharma Inc (AEON.WS) in Q1 2023, closing a stake of 83,333 shares — an estimated $4K sold.

HGC Investment Management first reported a position in AEON.WS in Q4 2022 and held it in 1 quarter. The position peaked at $4K in Q4 2022. 49 funds tracked by Wall St. Rank hold AEON.WS as of Q1 2023.

  • HGC Investment Management reported no remaining AEON Biopharma Inc position as of Q1 2023 after selling out during the quarter.
  • HGC Investment Management sold 83,333 AEON Biopharma Inc shares in Q1 2023, an estimated $4K.
  • HGC Investment Management first reported a position in AEON Biopharma Inc in Q4 2022 and held it in 1 quarter.
  • HGC Investment Management's AEON Biopharma Inc position peaked at $4K in Q4 2022.
  • 49 funds tracked by Wall St. Rank held AEON Biopharma Inc as of Q1 2023.

Based on HGC Investment Management's 13F filing for Q1 2023, filed 15 May 2023.